Mindset Pharma (OTCMKTS:MSSTF) vs. CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Contrast

CRISPR Therapeutics (NASDAQ:CRSP) and Mindset Pharma (OTCMKTS:MSSTF) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Institutional & Insider Ownership

69.2% of CRISPR Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for CRISPR Therapeutics and Mindset Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1	7	10	1	2.58
Mindset Pharma	0	0	0	0	0.00

CRISPR Therapeutics currently has a consensus price target of $67.78, suggesting a potential upside of 41.23%. Given CRISPR Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe CRISPR Therapeutics is more favorable than Mindset Pharma.

Profitability

This table compares CRISPR Therapeutics and Mindset Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Mindset Pharma	N/A	N/A	N/A

Valuation & Earnings

This table compares CRISPR Therapeutics and Mindset Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51 million	1,318.70	-$581.60 million	($6.22)	-7.72
Mindset Pharma	N/A	N/A	N/A	N/A	N/A

Mindset Pharma has lower revenue, but higher earnings than CRISPR Therapeutics.

Summary

CRISPR Therapeutics beats Mindset Pharma on 7 of the 10 factors compared between the two stocks.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

About Mindset Pharma

Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.